Last reviewed · How we verify
oxybutynin immediate release
oxybutynin immediate release is a Anticholinergic Small molecule drug developed by Astellas Pharma Inc. It is currently FDA-approved.
Oxybutynin is an anticholinergic that blocks muscarinic receptors in the bladder, leading to relaxation of the detrusor muscle and increased bladder capacity.
Oxybutynin immediate release is used to treat neurogenic detrusor overactivity, a condition associated with spinal cord injuries. It is also studied for its potential use in treating detrusor hyperreflexia and urinary bladder conditions in individuals with spinal cord injuries.
At a glance
| Generic name | oxybutynin immediate release |
|---|---|
| Sponsor | Astellas Pharma Inc |
| Drug class | Anticholinergic |
| Target | Muscarinic acetylcholine receptors (M2 and M3) |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | FDA-approved |
Mechanism of action
By blocking muscarinic receptors, oxybutynin reduces the involuntary contractions of the bladder muscle, which helps to control symptoms of overactive bladder.
Approved indications
Common side effects
- Dry mouth
- Constipation
- Dizziness
- Headache
- Nausea
- Fatigue
Drug interactions
- Antidepressants
- Antipsychotics
- Other anticholinergics
Key clinical trials
- Oxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial (NA)
- A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment (PHASE2)
- Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury (PHASE2)
- Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial (PHASE4)
- Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition (PHASE4)
- A Comparison Study of Oxybutynin and Botulinum Toxin for Neurogenic Detrusor Overactivity (NA)
- Cognitive Effects of Oral Oxybutynin and Oxybutynin Chloride Topical Gel in Older Volunteers (PHASE1)
- A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence. (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
| US5434174A |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oxybutynin immediate release CI brief — competitive landscape report
- oxybutynin immediate release updates RSS · CI watch RSS
- Astellas Pharma Inc portfolio CI
Frequently asked questions about oxybutynin immediate release
What is oxybutynin immediate release?
How does oxybutynin immediate release work?
Who makes oxybutynin immediate release?
What drug class is oxybutynin immediate release in?
What development phase is oxybutynin immediate release in?
What are the side effects of oxybutynin immediate release?
What does oxybutynin immediate release target?
Related
- Drug class: All Anticholinergic drugs
- Target: All drugs targeting Muscarinic acetylcholine receptors (M2 and M3)
- Manufacturer: Astellas Pharma Inc — full pipeline
- Therapeutic area: All drugs in Urology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing